Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Journal of Immunology Research|May 15, 2015
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1)Peter H Schafer, Peng Chen, Lorraine Fang, et al.Drugs in R&D|October 11, 2019
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in MicePeter H Schafer, Mary Adams, Gerald Horan, et al.Journal of Drugs in Dermatology : JDD|August 21, 2018
Mechanisms Underlying the Clinical Effects of Apremilast for PsoriasisCarlo Pincelli, Peter H Schafer, Lars E French, et al.Seminars in Oncology|April 30, 2003
Potential new therapeutics for Waldenstrom's macroglobulinemiaJerome B Zeldis, Peter H Schafer, Brydon L Bennett, et al.British Journal of Haematology|December 21, 2012
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expressionLing-Hua Zhang, Jolanta Kosek, Maria Wang, et al.Arthritis Research & Therapy|September 16, 2015
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectorsMiguel Perez-Aso, M Carmen Montesinos, Aránzazu Mediero, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 30, 2017
Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon ActivityYumi Nakayama, Jolanta Kosek, Lori Capone, et al.Leukemia Research|February 24, 2006
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assemblyAnita K Gandhi, Jian Kang, Syedah Naziruddin, et al.Radiology|May 26, 2012
Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapyErrol E Stewart, Hongtao Sun, Xiaogang Chen, et al.Plos One|November 19, 2013
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patientsAnita K Gandhi, Tao Shi, Mingyu Li, et al.Pageof 5